Abhijeet Danve, MBBS MD - Yale University - MD

Abhijeet Danve

MBBS MD

Yale University

MD

New Haven, CT | United States

Main Specialties: Rheumatology

Additional Specialties: Rhuematology

Abhijeet Danve, MBBS MD - Yale University - MD

Abhijeet Danve

MBBS MD

Introduction

Primary Affiliation: Yale University - New Haven, CT , United States

Specialties:

Additional Specialties:

Publications

6Publications

119Reads

-Profile Views

18PubMed Central Citations

Do Tumor Necrosis Factor (TNF) Inhibitors Improve the Glycemic Control in Patients with Rheumatoid Arthritis and Concomitant Diabetes Mellitus?

Am J Ther 2017 May;24(3):e347-e350

Divisions of 1Rheumatology and 2Diabetes, Endocrinology and Metabolism, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MJT.0000000000000297DOI Listing
May 2017
15 Reads
1.130 Impact Factor

Screening and referral for axial spondyloarthritis--need of the hour.

Clin Rheumatol 2015 Jun 7;34(6):987-93. Epub 2015 May 7.

Division of Rheumatology, University of Nebraska Medical Center, 983025 Nebraska Medical Center, Omaha, NE, 68198-3025, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-015-2958-2DOI Listing
June 2015
29 Reads
2 Citations
1.774 Impact Factor

IL-17 Inhibition in Axial Spondyloarthritis

Curr Treat Options in Rheum (2015) 1:221–230

Current Treatment Options in Rheumatology

Axial spondyloarthritis (axSpA) affects 0.5–1.5 % of western population. Although TNF inhibitor (TNFi) medications have dramatically improved the treatment of this disabling disease, there are almost 40 % of patients who do not respond or have intolerance to TNFi. Several genetic, animal model, translational, and clinical studies have confirmed the role of IL- 23/IL-17 pathway in the pathogenesis of the axSpA. This axis could be targeted upstream by inhibiting either IL-23 or IL-23 receptor (IL-23R) or downstream by blocking IL-17 or IL-1RA receptor. Ustekinumab, a monoclonal antibody against p40 subunit of IL-12 and IL-23, and secukinumab, a monoclonal antibody against IL-17, have both demonstrated significant beneficial effect in controlling the disease activity, quality of life, and physical function as well as MRI scores in axSpA. Combined IL-17 and TNF-α blockade is a novel option for the patients with axSpA, which needs to be investigated further. We need prospective trials to evaluate the effect of IL-23/IL-17 axis manipulation on the radiographic progression and also on the extra-articular manifestations of axSpA

View Article
April 2015
12 Reads

Routine Assessment of Patient Index Data 3 score (RAPID3) correlates well with Bath Ankylosing Spondylitis Disease Activity index (BASDAI) in the assessment of disease activity and monitoring progression of axial spondyloarthritis.

Clin Rheumatol 2015 Jan 26;34(1):117-24. Epub 2014 Nov 26.

Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR, 97239, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-014-2827-4DOI Listing
January 2015
35 Reads
7 Citations
1.774 Impact Factor

Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus: a case report.

Semin Arthritis Rheum 2014 Oct 6;44(2):195-7. Epub 2014 Jun 6.

Division of Arthritis and Rheumatic Diseases, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97006.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2014.05.006DOI Listing
October 2014
18 Reads
3 Citations
3.925 Impact Factor

Amyloid beta-related angiitis--a case report and comprehensive review of literature of 94 cases.

Semin Arthritis Rheum 2014 Aug 11;44(1):86-92. Epub 2014 Feb 11.

Division of Arthritis & Rheumatic Diseases (OP-09), Oregon Health & Science University, 3181, SW Sam Jackson Park Road, Portland, OR 97239.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2014.02.001DOI Listing
August 2014
22 Reads
6 Citations
3.925 Impact Factor

Top co-authors

Lisa Perry
Lisa Perry

Oregon Health and Science University

1
Marjorie Grafe
Marjorie Grafe

University of California

1
Alexis Dinno
Alexis Dinno

University of California

1
Kiana Vakil-Gilani
Kiana Vakil-Gilani

Legacy Emanuel Medical Center

1
Anusha Reddy
Anusha Reddy

University of Aberdeen

1
Supriya Kulkarni
Supriya Kulkarni

University of Rhode Island

1
Neha Garg
Neha Garg

University of Illinois at Urbana-Champaign

1